Colchicine in Patients with Chronic Coronary Disease

Cited by (1,001)

Items 701–800 of 1,001

1. Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications
   Francesco Perone, Marco Bernardi, Luigi Spadafora, Matteo Betti, Stefano Cacciatore, Francesco Saia, Federica Fogacci, Vikash Jaiswal, Elad Asher, Francesco Paneni et al. · 2025 · Journal of Cardiovascular Development and Disease
2. Pyroptosis in cardiovascular diseases: roles, mechanisms, and clinical implications
   Yuqing Niu, Li Wang, Yaoqing Zhang, Yanqiang Zou, Cheng Zhou · 2025 · Frontiers in Cardiovascular Medicine
3. Nanoparticle Drug Delivery Systems for Atherosclerosis: Precision Targeting, Inflammatory Modulation, and Plaque Stabilization
   Yunqi Zhang, Feifei Li, Libo Liu, Ziyu An, Hanzhong Luo, Huan Zhang, Rui Ma, Ruoxi Zhang, Qiong Dai, Mingduo Zhang et al. · 2025 · Advanced Science
4. Trained immunity in cardiovascular disease
   Niels Peter Riksen, Mihai Gheorghe Netea, Hafid Ait‐Oufella, Triantafyllos Chavakis, George Hajishengallis · 2025 · European Heart Journal
5. Effect of Colchicine in Reducing Inflammatory Biomarkers and Cardiovascular Risk in Coronary Artery Disease: A Meta-analysis of Clinical Trials
   Sujitha Sethuramalingam, Rituparna Maiti, Debasish Hota, Anand Srinivasan · 2021 · American Journal of Therapeutics
6. Recent Advances on the Role and Therapeutic Potential of Regulatory T Cells in Atherosclerosis
   Toru Tanaka, Naoto Sasaki, Yoshiyuki Rikitake · 2021 · Journal of Clinical Medicine
7. Association of colchicine use for acute gout with clinical outcomes in acute decompensated heart failure
   Mary E. Roth, Melissa E. Chinn, Steven P. Dunn, Kenneth C. Bilchick, Sula Mazimba · 2022 · Clinical Cardiology
8. Depletion of Foxp3+ regulatory T cells augments CD4+ T cell immune responses in atherosclerosis-prone hypercholesterolemic mice
   Kazuyuki Kasahara, Naoto Sasaki, Hilman Zulkifli Amin, Toru Tanaka, Sayo Horibe, Tomoya Yamashita, Ken‐ichi Hirata, Yoshiyuki Rikitake · 2022 · Heliyon
9. Natural products against inflammation and atherosclerosis: Targeting on gut microbiota
   Bing Deng, Liyu Tao, Yiru Wang · 2022 · Frontiers in Microbiology
10. Advances in the Assessment of Coronary Artery Disease Activity with PET/CT and CTA
    Jacek Kwieciński, Rafał Wolny, Alicja Chwała, Piotr J. Slomka · 2023 · Tomography
11. Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease
    T J Van Trier, Marjolein Snaterse, Steven H J Hageman, Nienke ter Hoeve, Madoka Sunamura, Eric P. Moll van Charante, Henrike Galenkamp, Jaap Willem Deckers, Fabrice M A C Martens, Frank L.J. Visseren et al. · 2023 · European Journal of Preventive Cardiology
12. A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome
    Motoaki Sano · 2023 · International Journal of Molecular Sciences
13. Neutrophils in Health and Disease: From Receptor Sensing to Inflammasome Activation
    Agnieszka Iwaniuk, Ewa Jabłońska · 2023 · International Journal of Molecular Sciences
14. The Role Played by Novel Inflammatory Markers in Assessment of Peripheral Artery Disease
    Viviana Onofrei, Adrian Silviu Crişan, Cristina Andreea Adam, Dragoș Traian Marius Marcu, Mihai Ștefan Cristian Haba, Laura Carina Tribus, Alexandr Ceasovschih, Irina Eşanu, Antoneta Dacia Petroaie, Radu Adrian Crișan-Dabija et al. · 2023 · Medicina
15. New Targets in Atherosclerosis: Vascular Smooth Muscle Cell Plasticity and Macrophage Polarity
    Michael Hutton, Madeleine Frazer, Alexander Lin, Sanjay Patel, Ashish Misra · 2023 · Clinical Therapeutics
16. Novel Therapeutic Approaches to Prevent Atherothrombotic Ischemic Stroke in Patients with Carotid Atherosclerosis
    Núria Puig, Arnau Solé, Ana Aguilera‐Simón, Raquel Griñán, Noemí Rotllán, Pol Camps‐Renom, Sònia Benítez · 2023 · International Journal of Molecular Sciences
17. Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trial
    Niekbachsh Mohammadnia, Jan Los, Tjerk S.J. Opstal, Aernoud T.L. Fiolet, John W. Eikelboom, Arend Mosterd, Stefan Mark Nidorf, Charley Ann Budgeon, Jan G.P. Tijssen, Peter Lindsay Thompson et al. · 2023 · Frontiers in Cardiovascular Medicine
18. Colchicine ameliorates short-term abdominal aortic aneurysms by inhibiting the expression of NLRP3 inflammasome components in mice
    Jiaxin Hu, Jiamin Xu, Jiling Zhao, Yuwei Liu, Rui Huang, Dejiang Yao, Jun Xie, Yuhua Lei · 2023 · European Journal of Pharmacology
19. The impact of colchicine on patients with acute and chronic coronary artery disease
    Mehdi Madanchi, Mabelle Young, Gregorio Tersalvi, Giacomo Maria Cioffi, Adrian Attinger‐Toller, Florim Cuculi, Reto Kurmann, Matthias Bossard · 2024 · European Journal of Internal Medicine
20. Inflammatory risk and clinical outcomes according to polyvascular atherosclerotic disease status in patients undergoing PCI
    Benjamin Bay, Birgit Vogel, Raman Sharma, Samantha Sartori, Pier Pasquale Leone, Mashal Nathani, Angelo Oliva, Kenneth F. Smith, Amit Hooda, Joseph Michael Sweeny et al. · 2024 · Clinical Research in Cardiology
21. Colchicine for the treatment of the spectrum of cardiovascular diseases: current evidence and ongoing perspectives
    Massimo Imazio, Cosimo Agrimi, Laura Cescon, Giovanni Panzolli, Valentino Collini, Gianfranco Sinagra · 2024 · Journal of Cardiovascular Medicine
22. Uric acid and cardiovascular diseases: a reappraisal
    Akruti Patel Prabhakar, Angel López‐Candales · 2024 · Postgraduate Medicine
23. Overview of multifunctional Tregs in cardiovascular disease: From insights into cellular functions to clinical implications
    Vipin Kumar, Megumi Narisawa, Xian Wu Cheng · 2024 · The FASEB Journal
24. Colchicine in Patients With Coronary Disease Who Underwent Coronary Artery Bypass Surgery: A Meta-Analysis of Randomized Controlled Trials
    Hristo Kirov, Tulio M. M. Caldonazo, Angelique Runkel, Darko Medin, Johannes Fischer, Luis Roberto Dallan, Murat Mukharyamov, Omar Asdrúbal Vilca Mejía, Fábio Biscegli Jatene, Torsten Doenst · 2024 · The American Journal of Cardiology
25. Colchicine in Coronary Artery Disease: Where Do We Stand?
    Aldo Bonaventura, Nicola Potere, Luca Liberale, Simon C Kraler, Brittany N. Weber, Antonio Abbate · 2025 · Journal of Cardiovascular Pharmacology
26. Update on Preclinical Models of Cancer Therapy-Related Cardiac Dysfunction: Challenges and Perspectives. A Scientific Statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart
    Alessandra Ghigo, Pietro Ameri, Aarti H. Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios T. Farmakis, Arantxa González, Stephane R B Heymans, Borja Ibáñez, Teresa López‐Fernández et al. · 2025 · European Journal of Heart Failure
27. Colchicine in Patients with Coronary Artery Disease with or Without Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials
    Michał Kuzemczak, Abdalazeem Ibrahem, Mohammad Alkhalil · 2021 · Clinical Drug Investigation
28. Clinical utility of coronary artery computed tomography angiography- What we know and What's new?
    Mahmoud Al Rifai, Ahmed Ibrahim Ahmed, Fares Alahdab, Mouaz Husayn Al-Mallah · 2022 · Progress in Cardiovascular Diseases
29. Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management?
    Nathalie Conrad, Iain B. McInnes, John J.V. McMurray, Naveed A. Sattar · 2022 · Annals of the Rheumatic Diseases
30. Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted Therapy
    Michael Joseph Blaha, Harpreet Singh Bhatia · 2024 · Journal of the American College of Cardiology
31. Novel Insight into Inflammatory Pathways in Acute Pulmonary Embolism in Humans
    Anna M. Imiela, Tomasz P Mikolajczyk, Piotr Pruszczyk · 2024 · Archivum Immunologiae et Therapiae Experimentalis
32. Inflammasome Activation and Neutrophil Extracellular Traps in Atherosclerosis
    Tadayoshi Karasawa, Masafumi Takahashi · 2025 · Journal of Atherosclerosis and Thrombosis
33. Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS)
    Lei Lv, Jigar R. Rajpura, Meixia Liu, Matt Strum, Benjamin J. Chastek, Jonathan Johnson, Ty J. Gluckman · 2025 · American Journal of Preventive Cardiology
34. Inflammasomes as the molecular hub of cardiovascular-metabolic-immune comorbidity networks
    Xingyu Qian, Jian M. Sun, Fei Li, Xu Li, Xingjian Hu, Nianguo Dong, Guangzhou Li · 2025 · Frontiers in Immunology
35. Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial
    Rouchelle Sriranjan, Tian X. Zhao, Stephen Paul Hoole, Simon James Bond, Jason M. Tarkin, Jacob Brubert, Annette Hubsch, Joanna Helmy, Elaine Bumanlag-Amis, Navazh Jalaludeen et al. · 2026 · Nature Medicine
36. Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis
    Anubodh Sunny Varshney, David E. Wang, Ankeet S. Bhatt, Alexander J. Blood, Musa A. Sharkawi, Hasan Khalid Siddiqi, Muthiah Vaduganathan, Peter Philip Monteleone, Manesh R. Patel, W. Schuyler Jones et al. · 2020 · American Heart Journal
37. Lipoxins reduce obesity-induced adipose tissue inflammation in 3D-cultured human adipocytes and explant cultures
    Matúš Soták, Meenu Rohini Rajan, Madison Clark, Matthew Harms, Alankrita Rani, Jamie Dale Kraft, David Tandio, Tong Shen, Kamil Borkowski, Oliver Fiehn et al. · 2022 · iScience
38. Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction
    John W. Ostrominski, Muthiah Vaduganathan · 2023 · The American Journal of Medicine
39. Colchicine attenuates the electrical remodeling of post-operative atrial fibrillation through inhibited expression of immune-related hub genes and stabilization of microtubules
    Hangying Ying, Wenpu Guo, Xiaomei Tang, Jun Pan, Pengcheng Yu, Hangping Fan, Xiaochen Wang, Ruhong Jiang, Chenyang Jiang, Ping Liang · 2023 · International Journal of Biological Sciences
40. Relationship Between Social Skills and Social Support with Peers' Academic Confidence on Boarding High School Students
    Anisa Agustanti, Kamsih Astuti · 2022 · Journal International Dakwah and Communication
41. LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?
    Tse Wing Winnie Ho, Andria Henry, Warren L. Lee · 2023 · Current Atherosclerosis Reports
42. Association of Mild Kidney Dysfunction with Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
    Robin W.M. Vernooij, Anne Margje Lisa Naomi van Ommen, Gideon Valstar, Maarten Jan Cramer, Arco J. Teske, Roxana Menken, Leo Hofstra, Frans Hendrik Rutten, Michiel L. Bots, Hester M. den Ruijter et al. · 2023 · ESC Heart Failure
43. Coronary Plaque Characteristics and Underlying Mechanism of Acute Coronary Syndromes in Different Age Groups of Patients With Diabetes
    Keishi Suzuki, Takayuki Niida, Haruhito Yuki, Daisuke Kinoshita, Daichi Fujimoto, H Lee, Iris A. McNulty, Masamichi Takano, Sunao Nakamura, Tsunekazu Kakuta et al. · 2023 · Journal of the American Heart Association
44. Systemic inflammation among adults with diagnosed and undiagnosed cardiometabolic conditions: a potential missed opportunity for cardiovascular disease prevention
    Arch G. Mainous, Pooja Sharma, Ara Jo · 2024 · Frontiers in Medicine
45. Salicylic acid modulates secondary metabolism and enhanced colchicine accumulation in long yellow daylily (Hemerocallis citrina)
    Yeminzi Miao, Hanmei Li, Junjie Pan, Binxiong Zhou, Tianjun He, Yanxun Wu, Dayun Zhou, Weimin He, Limin Chen · 2024 · AoB Plants
46. Long COVID as a disease of accelerated biological aging: An opportunity to translate geroscience interventions
    Areez Shafqat, Mary Clare Masters, Utkarsh Tripathi, Tamar Tchkonia, James L. Kirkland, Shahrukh Khurshid Hashmi · 2024 · Ageing Research Reviews
47. The admission level of CRP during cardiogenic shock is a strong independent risk marker of mortality
    François Roubille, Miloud Cherbi, Eran Kalmanovich, Quentin Delbaere, Eric Bonnefoy‐Cudraz, Étienne Puymirat, Guillaume Schurtz, Édouard Gerbaud, Laurent Bonello, Pascal Lim et al. · 2024 · Scientific Reports
48. Targeting Cyclophilin A in the Cardiac Microenvironment Preserves Heart Function and Structure in Failing Hearts
    Manuel Sigle, Anne‐Katrin Rohlfing, Melanie Cruz Santos, Timo Kopp, Konstantin Krutzke, Vincent Gidlund, Ferdinand Kollotzek, Julia Marzi, Saskia N. I. von Ungern‐Sternberg, Antti Poso et al. · 2024 · Circulation Research
49. Endothelial Shear Stress Metrics Associate With Proinflammatory Pathways at the Culprit Site of Coronary Erosion
    Mona Ahmed, David M. Leistner, Diaa A. Hakim, Youssef S. Abdelwahed, Ahmet Umit Coskun, Charles C. Maynard, Claudio Seppelt, Gregor Nelles, Denitsa Meteva, Nicholas V. Cefalo et al. · 2024 · JACC Basic to Translational Science
50. Rare damaging CCR2 variants are associated with lower lifetime cardiovascular risk
    Marios K. Georgakis, Rainer Malik, Omar El Bounkari, Natalie R. Hasbani, Jiang Li, Jennifer E. Huffman, Gabrielle E. Shakt, Reinier W. P. Tack, Tamara N. Kimball, Yaw Asare et al. · 2025 · Genome Medicine
51. Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort
    Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A. Bax, John W. Eikelboom, Arend Mosterd, Aernoud T.L. Fiolet, Jan G.P. Tijssen, Peter L. Thompson, Dominique P.V. de Kleijn, Sotirios Tsimikas et al. · 2025 · Atherosclerosis
52. Prediction of 10-year mortality using hs-CRP in Chinese people with hyperglycemia: Findings from the Da Qing diabetes prevention outcomes study
    Xin Qian, Siyao He, Jinping Wang, Qiuhong Gong, Yali An, Hui Li, Yanyan Chen, Guangwei Li · 2021 · Diabetes Research and Clinical Practice
53. Impact of coronary artery calcium testing on patient management
    Wanda Y. Wu, David W. Biery, Adam N. Berman, Grace Hsieh, Sanjay Divakaran, Sumit Gupta, Michael L. Steigner, Ayaz Aghayev, Hicham Skali, Donna M. Polk et al. · 2021 · Journal of cardiovascular computed tomography
54. Colchicine Does Not Reduce Abdominal Aortic Aneurysm Growth in a Mouse Model
    James Klemens Phieter Phie, Shivshankar Thanigaimani, Pacific Huynh, Raghuveeran Anbalagan, Corey Stephen Moran, Robert Tumwesigye Kinobe, Joseph Vaughan Moxon, Matthew A. Field, Smriti Murali Krishna, Jonathan Golledge · 2022 · Cardiovascular Therapeutics
55. High-sensitivity C-reactive protein, plaque vulnerability and adverse events in patients with stable coronary disease: An optical coherence tomography study
    Masahiro Katamine, Yoshiyasu Minami, Takako Nagata, Kiyoshi Asakura, Yusuke Muramatsu, Daisuke Kinoshita, Kazuhiro Fujiyoshi, Junya Ako · 2024 · International Journal of Cardiology
56. Experimental evidence on colchicine's mode of action in human carotid artery plaques
    Alexander von Ehr, Ines Derya Steenbuck, Charlotte Häfele, Felix Remmersmann, Tamara Antonela Vico, Carolin A. Ehlert, Diana Lindner, Dennis Wolf, Stefan Tholen, Oliver Schilling et al. · 2025 · Atherosclerosis
57. Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial
    Niekbachsh Mohammadnia, Britta E. Wesselink, Willem A. Bax, Stefan Mark Nidorf, Arend Mosterd, Aernoud T.L. Fiolet, Aysun Cetinyurek‐Yavuz, Peter Lindsay Thompson, Shrikant I. Bangdiwala, John W. Eikelboom et al. · 2025 · Journal of the American Heart Association
58. Cardioprotection Reloaded: Reflections on 40 Years of Research
    Pasquale Pagliaro, Giuseppe Alloatti, Claudia Renata Rezende Penna · 2025 · Antioxidants
59. Coronary Artery Disease and Atherosclerosis in Other Vascular Districts: Epidemiology, Risk Factors and Atherosclerotic Plaque Features
    Michele Russo, Filippo Luca Gurgoglione, Alessandro Russo, Riccardo Rinaldi, Laura Torlai Triglia, Matteo Foschi, Carlo Vigna, Rocco Vergallo, Rocco Antonio Montone, Umberto Benedetto et al. · 2025 · Life
60. Glucocorticoid induced TNF receptor family-related protein (GITR) – A novel driver of atherosclerosis
    Laura A. Bosmans, Annelie Shami, Dorothee Atzler, Christian Weber, Isabel Gonçalves, Esther Lutgens · 2021 · Vascular Pharmacology
61. Colchicine for the prevention of ischemic stroke
    Ayman Al‐Atta, Michał Kuzemczak, Mohammad Alkhalil · 2021 · Brain Circulation
62. Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management
    Atsushi Sakamoto, Anne Cornelissen, Yu Sato, Masayuki Mori, Rika Kawakami, Kenji Kawai, Saikat Kumar B. Ghosh, Weili Xu, Biniyam Abebe, Armelle Dikongue et al. · 2022 · US Cardiology Review
63. Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach
    Rasmus R. Mikkelsen, Malthe Pallesgaard Hundahl, Christopher Kirkegaard Torp, Javier Rodríguez‐Carrio, Mads Kjølby, Jens Meldgaard Bruun, Tue Wenzel Kragstrup · 2022 · European Journal of Pharmacology
64. Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease
    Gabrielle J. Pennings, Caroline J. Reddel, Vivien Mun Yee Chen, Sonali Rukshana Gnanenthiran, Leonard Kritharides · 2023 · Frontiers in Cardiovascular Medicine
65. Impact of C-Reactive Protein on Long-Term Cardiac Events in Stable Coronary Artery Disease Patients with Chronic Kidney Disease
    Kotaro Tokuda, Akihito Tanaka, Akihiro Tobe, Yoshinori Shirai, Masanari Kurobe, Yoshiaki Kubota, Takeshige Kunieda, Tatsuya Miyazaki, Koji Mizutani, Kenji Furusawa et al. · 2023 · Journal of Atherosclerosis and Thrombosis
66. Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
    Hans Carl Hasselbalch, Peter Junker, Vibe Skov, Lasse Kjær, Trine Alma Knudsen, Morten Kranker Larsen, Morten Orebo Holmström, Mads Hald Andersen, Christina Jensen, M.A. Karsdal et al. · 2023 · Cancers
67. Prognostic significance of inflammation in patients with coronary artery disease at low residual inflammatory risk
    Tianyu Li, Peizhi Wang, Xiaozeng Wang, Zhenyu Liu, Zheng Zhang, Yongzhen Zhang, Zhifang Wang, Yingqing Feng, Qingsheng Wang, Xiaogang Guo et al. · 2023 · iScience
68. Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis
    William B. Song, Daniel E. Soffer, Joel M. Gelfand · 2024 · Dermatologic Clinics
69. Aiming at early-stage vulnerable plaques: A nanoplatform with dual-mode imaging and lipid-inflammation integrated regulation for atherosclerotic theranostics
    Yao Wang, Zhebin Chen, Qiongjun Zhu, Zhezhe Chen, Guosheng Fu, Boxuan Ma, Wenbin Zhang · 2024 · Bioactive Materials
70. Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation
    Robert S. Zhang, Brittany Weber, Diego Araiza Garaygordobil, Michael Seth Garshick · 2024 · Current Cardiology Reports
71. The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease
    Michael Khorsandi, Roger Scott Blumenthal, Michael Joseph Blaha, Payal Kohli · 2024 · Clinical Cardiology
72. The role of residual inflammatory risk and LDL cholesterol in patients with in-stent restenosis undergoing percutaneous coronary intervention
    Han Zhang, Chujie Zhang, Yin Zhang, Tao Tian, Tianjie Wang, Jue Chen, Jie Qian, Fenghuan Hu, Kefei Dou, Shubin Qiao et al. · 2024 · Journal of clinical lipidology
73. Genetic and epigenetic regulation of inflammasomes: Role in atherosclerosis
    Mustafa Yalçınkaya, Alan R. Tall · 2024 · Atherosclerosis
74. Reversal of Atherosclerotic Plaque Growth and Vulnerability: Effects of Lipid-Modifying and Anti-Inflammatory Therapeutic Agents
    Michail I. Papafaklis, Rafail Koros, Grigorios Tsigkas, Αντώνιος Καρανάσος, Αθανάσιος Μούλιας, Periklis A. Davlouros · 2024 · Biomedicines
75. A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy?
    Timo E. Strandberg, Peter Libby, Petri T. Kovanen · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
76. Colchicine as an Alternative First-Line Treatment of Sclerosing Mesenteritis: A Retrospective Study
    Pedro Cortés, Hassan M. Ghoz, Obaie Mzaik, Muhamad Alhaj Moustafa, Yan Bi, Bhaumik S. Brahmbhatt, Nader D. Daoud, Maoyin Pang · 2021 · Digestive Diseases and Sciences
77. Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
    Carlos I. Ponte-Negretti, Fernando Wyss, Daniel Leonardo Piskorz, Raul D. Santos, Raul Villar, Alberto Lorenzatti, Patricio A López-Jaramillo, Peter P. Toth, A. Juan J. Amaro, Alfonso K. Rodrigo et al. · 2021 · Archivos de cardiología de México
78. Perivascular Adipose Tissue Attenuation on Computed Tomography beyond the Coronary Arteries. A Systematic Review
    Domenico Tuttolomondo, Chiara Martini, Francesco Nicolini, Francesco Formica, Alessandro Pini, Francesco Secchi, Riccardo Volpi, Massimo De Filippo, Nicola Gaibazzi · 2021 · Diagnostics
79. Pre-Operative Plasma Extracellular Vesicle Proteins are Associated with a High Risk of Long Term Secondary Major Cardiovascular Events in Patients Undergoing Carotid Endarterectomy
    Nathalie Timmerman, Farahnaz Waissi, Mirthe Dekker, Qiu Ying van de Pol, Joëlle van Bennekom, Arjan H. Schoneveld, Marjet J.M. klein Avink, Robbert J. de Winter, Gerard Pasterkamp, Gert Jan de Borst et al. · 2021 · European Journal of Vascular and Endovascular Surgery
80. Colchicine for cardiovascular therapy: A drug interaction perspective and a safety meta-analysis
    Selçuk Şen, Istanbul-Turkey, Eda Karahan, Cansu Büyükulaş, Yasin Onur Polat, Ali Yağız Üresin · 2021 · The Anatolian Journal of Cardiology
81. A Meta-Analysis Evaluating the Colchicine Therapy in Patients With Coronary Artery Disease
    Stefan Grajek, Michał Michalak, Tomasz Urbanowicz, Anna Olasińska‐Wiśniewska · 2021 · Frontiers in Cardiovascular Medicine
82. Colchicine for symptomatic coronary artery disease after percutaneous coronary intervention
    Kah Long Aw, Amanda Koh, Han Lin Lee, Aurimas Kudzinskas, Rodney De Palma · 2022 · Open Heart
83. Anti-inflammatory strategies for atherosclerotic artery disease
    Federica Giuseppa Agnello, Davide Capodanno · 2022 · Expert Opinion on Drug Safety
84. Endoplasmic reticulum stress: A common pharmacologic target of cardioprotective drugs
    Arshag D. Mooradian, Michael John Haas · 2022 · European Journal of Pharmacology
85. The heterogeneous cellular landscape of atherosclerosis: Implications for future research and therapies. A collaborative review from the EAS young fellows
    Fabrizia Bonacina, Alessia Di Costanzo, V. V. Genkel, Xiang Yi Kong, Jeffrey Kroon, Ena Stimjanin, Dimitrios Tsiantoulas, Mandy O. J. Grootaert · 2023 · Atherosclerosis
86. Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction
    Moman A. Mohammad, Sasha M. Koul, Anna Egerstedt, J. Gustav Smith, Marko Noč, Irene Marthe Lang, Michael S. Holzer, Peter Michael Clemmensen, Olof Gidlöf, Bernhard Metzler et al. · 2020 · Scientific Reports
87. Association Between Colchicine Treatment and Clinical Outcomes in Patients with Coronary Artery Disease: Systematic Review and Meta-analysis
    Francesco Condello, Matteo Sturla, Bernhard Reimers, Gaetano Liccardo, Giulio Giuseppe Stefanini, Gianluigi Condorelli, Giuseppe Ferrante · 2021 · European Cardiology Review
88. Colchicine promotes atherosclerotic plaque stability independently of inflammation
    Weizhen Li, Alexander Lin, Michael Hutton, Harkirat Dhaliwal, James Nadel, Julie Rodor, Sergey Tumanov, Tiit Örd, Matthew Kyle Hadden, Michal Mokrý et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
89. Bone Marrow Niche in Cardiometabolic Disease: Mechanisms and Therapeutic Potential
    Zachary A. Kohutek, Heather L. Caslin, Daniel J. Fehrenbach, Jonathan Brett Heimlich, Jonathan D. Brown, Meena S. Madhur, Paul Brent Ferrell, Amanda C. Doran · 2025 · Circulation Research
90. The various roles of TREM2 in cardiovascular disease
    Shuai Wang, Chenghui Cao, Daoquan Peng · 2025 · Frontiers in Immunology
91. Is It Time to Revisit the Role of Interleukin-1 Inhibitors in Osteoarthritis?
    Martín Brom, Franziska Saxer, Linda Mindeholm, Matthias Schieker, Philip G. Conaghan · 2025 · Diabetes Metabolic Syndrome and Obesity
92. Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARα improves atherosclerosis in Ldlr- deficient mice
    Doriane Henry, Eric Baugé, Nathalie Hennuyer, Kévin Ory, Bruno Derudas, Emmanuelle Vallez, Audrey Deprince, Philippe Lefèbvre, Joel T. Haas, Bart Staels et al. · 2025 · Science Translational Medicine
93. High-sensitivity C-reactive protein mediates age-related vascular dysfunction: the Rotterdam study
    Soroush Mohammadi Jouabadi, Annique Claringbould, A.H. Jan Danser, Bruno H. Ch. Stricker, Maryam Kavousi, Anton J.M. Roks, Fariba Ahmadizar · 2025 · European Journal of Preventive Cardiology
94. Curcumin-loaded nanoscale coordination polymers for ROS scavenging and anti-inflammatory therapy in atherosclerosis
    Song Z. Ding, Wenyi Xu, Xueliang Liu, Zhijun Wu, Xiaolei He, Yue Huang, Jiyuan Chen, Wei Yao, Huayuan Zhou, Yu Pu Yang et al. · 2025 · Materials Today Bio
95. Role of Diverse Smooth Muscle Cell Phenotypic Transitions in Atherosclerosis Development and Late-Stage Pathogenesis
    Vlad Serbulea, James Martin, Gary K. Owens · 2025 · Annual Review of Physiology
96. Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention
    Imma Forzano, Domenico Florimonte, Viviana Narciso, Mario Enrico Canonico, Domenico Simone Castiello, Lina Manzi, Stefano Cristiano, Alessandra Maria Spinelli, Donato Maria Vallone, Dario D’Alconzo et al. · 2025 · Journal of Clinical Medicine
97. LDL oxidation and cerebrovascular aging: mechanisms of endothelial dysfunction, inflammation, and vascular cognitive impairment and dementia
    Jennifer Ihuoma, Madison Milan, Sharon Negri, Eva Troyano‐Rodriguez, Rakesh Rudraboina, Aleksandra Kosmider, Shantipriya Awasthi, Anna Csiszar, Zoltan I. Ungvari, Andriy Yabluchanskiy et al. · 2026 · Redox Biology
98. Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
    Guiomar Mendieta, Paul M. Ridker, Barry A. Borlaug, Anique Ducharme, Carolyn S.P. Lam, Adriaan A. Voors, Pernille Auerbach, Maja Čikeš, Marat Fudim, Anders Hvelplund et al. · 2026 · European Journal of Heart Failure
99. Bayesian Analyses of Cardiovascular Trials—Bringing Added Value to the Table
    James M. Brophy · 2021 · Canadian Journal of Cardiology
100. Effects of colchicine on lipolysis and adipose tissue inflammation in adults with obesity and metabolic syndrome
     Jordan A. Levine, Zahra Sarrafan‐Chaharsoughi, Tushar P Patel, Sheila M. Brady, Krishna Karthik Chivukula, Emily K. Miller, Jung Min Han, Vipul Periwal, Anna T Wolska, Alan Thomas Remaley et al. · 2022 · Obesity